Impax Laboratories (IPXL) provides an update on a warning letter it received about its Hayward...

|By:, SA News Editor

Impax Laboratories (IPXL) provides an update on a warning letter it received about its Hayward facility, saying that the goal of closing out the warning letter by the end of February might not be met. Until the re-inspection of the facility passes, pending drug applications listing the Hayward location as a manufacturing site may be withheld by the FDA.